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Background:  Fabry  disease,  an  X-linked  lysosomal  sphingolipid  storage  disorder  caused  by mutation  of
the  -galactosidase  A  (GLA)  gene,  results  in systemic  organ  damage.  However,  the  age  of  onset  of clinical
manifestations  and  course  of the  disease  are  variable  even  within  the  same  family.
Objective:  In this  study,  we  evaluated  the  clinical  phenotype  and  the  molecular  lesions  associated  with  the
GLA gene  in a Japanese  family  with  Fabry  disease  that  predominantly  showed  cardiac  and  neurological
manifestations.
Methods:  A genetic  analysis  of  the  GLA  gene  using  conventional  genomic  sequencing  was  performed
in  all  seven  members  of this  family,  including  four  hemizygous  males  and  three  heterozygous  females.
Endomyocardial  biopsy  was  performed  in  two  patients  with  severe  left  ventricular  (LV)  hypertrophy.
Results:  A  novel  missense  mutation  was  identiﬁed  at codon  220  in exon  5, thus  resulting  in  an  arginine
to  proline  substitution  (R220P)  in  all seven  family  members.  The  three  adult  hemizygous  males  had
LV  hypertrophy  and  developed  neurological  manifestations  in  their  50  s. One  of the  adult  hemizygotes
developed  complete  atrioventricular  block.  On  the  other  hand,  we  could  not  ﬁnd  any  organ  damage  in  a
young hemizygous  male  or the  three  heterozygous  females.
Conclusion:  We  identiﬁed  a novel  missense  mutation  in  a Japanese  family  with  Fabry  disease  showing
cardiac  and  neurological  manifestations.  In  patients  with  Fabry  disease,  advanced  organ  damage  in  the
e-thr
3  Japheart and brain  can  be  lif
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Fabry disease is an X-linked sphingolipid storage disorder,
aused by mutations in the -galactosidase A (GLA) gene, which
esults in the systemic intralysosomal accumulation of glyco-
phingolipids throughout the body, particularly in the skin, nervous
ystem, eyes, kidneys, and heart [1]. This disease typically presents
uring childhood or adolescence. Clinical manifestations usually
ecome apparent around the age of 10 years in affected males
nd several years later in females. In general, the ﬁrst signs
nd symptoms reﬂect the damage to small nerve ﬁbers, result-
ng in peripheral neuropathic pain in the feet and hands [2–4].
ith age, various complications involving the kidneys, heart,
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ttp://dx.doi.org/10.1016/j.jjcc.2013.02.012eatening,  even  if renal  failure  is  lacking.
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and brain cause considerable morbidity and premature death
[5,6]. Renal failure has been found to be a frequent cause of
death, while the importance of cardiac disease is now increas-
ingly being recognized [6]. In terms of the clinical aspects, these
manifestations can present in patients at different times through-
out their life, contributing to the complicated phenotype of this
disease.
To date, a variety of disease-related mutations including
missense, nonsense, and splice-site mutations have been docu-
mented in cases of Fabry disease [7]. However, the analysis of
genotype–phenotype correlations in Fabry disease is complicated
by a number of factors. First, there is a high proportion of private
mutations, that is, most of the families carry different mutations
[8]. Second, there is a high degree of clinical variability both among
patients from the same family and among those from unrelated
families with the same mutation. Therefore, it is difﬁcult to predict
the exact clinical phenotype of each patient based only on their
genotype.
vier Ltd. All rights reserved.
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We  herein present a Japanese family with Fabry disease due to
 novel missense mutation, R220P. Clinically, all adult male mem-
ers of this family predominantly showed cardiac and neurological
anifestations in their 50 s. Thus, we will additionally discuss the
linical phenotype of Fabry disease in relation to the ﬁndings from
his family.
ethods
We  studied seven members of a three-generation family. All
even of these family members provided their written, informed
onsent in accordance with the principles of the Declaration of
elsinki. The medical records of each participant, which included
nterviews, physical examinations, blood and urine tests, and radio-
raphy were reviewed. The estimated glomerular ﬁltration rate
eGFR) was calculated using a validated equation described in the
odiﬁcation of Diet in Renal Disease study in Japan [9].
nzyme activity
The plasma GLA activity was measured in all seven members of
his family. The assay was performed using the method described
y Nakao et al. [10] using 5 ml  of a heparinized blood sample.
he normal values averaged 8.4 ± 2.4 nmol/ml/h (range 4.8–17.6)
n samples obtained from 89 normal males who were aged 52 ± 19
range 14–80) years.
ene analysis
Genomic DNA was isolated from whole blood using a standard
rocedure [11]. A mutation analysis was performed by polymerase
hain reaction (PCR) amplifying each of the seven GLA exons and
heir ﬂanking intronic sequences from genomic DNA using the
rimers shown in Table 2. Sequencing reactions were performed
sing the BigDye Terminatory v3.1 Cycle Sequencing Kit (Applied
iosystems, Foster City, CA, USA) according to the manufacturer’s
nstructions. Sequencing was performed on an ABI PRISM 3100
enetic Analyzer (Applied Biosystems).
ardiac examinations
Echocardiography and electrocardiography (ECG) were per-
ormed in all adult hemizygotes. M-mode echocardiographic
easurements of the left ventricular (LV) diameters and interven-
ricular septal and LV posterior wall thicknesses were performed
ccording to the recommendations of the American Society of
chocardiography [12]. Coronary angiography and endomyocardial
iopsy of the LV were performed in subjects II/1 and II/2.
erve conduction study
A nerve conduction study was performed in subject II/2. In this
tudy, the compound muscle action potential and nerve conduction
elocity were recorded on the right side of the median nerve, ulnar
erve, tibial nerve, peroneal nerve, and sural nerve.
istological studies
Heart tissue biopsy specimens from subjects II/1 and II/2 were
xed in 10% buffered formalin, and the sections were stained with
ematoxylin and eosin (H&E) and Azan–Mallory staining for histo-
ogical examination. The tissue block used for electron microscopy
as dehydrated with ethanol and embedded in propylene oxide
nd epoxy resin to prepare ultra-thin sections, which were stained
ith uranyl acetate and lead.rdiology 62 (2013) 63–69
Results
Subject II/2 (proband)
The proband, subject II/2 was  a 57-year-old male, who was
admitted to our hospital to be investigated for repeated episodes
of fainting with unconsciousness under resting conditions. A brain
computed tomography did not uncover any signiﬁcant abnormal
ﬁndings. However, his chest X-ray showed an enlargement of the
heart shadow, and ECG displayed high voltages, intraventricu-
lar conduction disturbance, and negative T waves in leads, I, II,
III, aVL, aVF, and V3–6 (Fig. 1). Furthermore, echocardiography
detected severe LV hypertrophy with a preserved ejection fraction
(Fig. 2). His other laboratory data showed proteinuria with a slightly
reduced eGFR, increased B-type natriuretic peptide, and an absence
of plasma GLA activity (Table 1). We therefore diagnosed the patient
to have Fabry disease. We  could not ﬁnd any other speciﬁc evidence
of this disease in his eyes, skin, or ears, but he did have a past his-
tory of painful peripheral neuropathy (acroparesthesias) during his
childhood.
During this admission, we detected a 15 beats run of asymp-
tomatic non-sustained ventricular tachycardia in his monitoring
ECG. Two  days after this arrhythmia occurred, he presented with
a loss of consciousness and complete atrioventricular block. We
performed emergency temporary cardiac pacing and subsequently
implanted an implantable cardioverter-deﬁbrillator (ICD). Cardiac
catheterization showed no signiﬁcant coronary artery stenosis. The
results from an endomyocardial biopsy showed interstitial ﬁbrosis
and cardiomyocyte hypertrophy with cytoplasmic vacuolization,
which are the typical histological ﬁndings of the heart in patients
with Fabry disease. In a nerve conduction study, the peroneal
nerve showed a low level of compound muscle action potential
(ankle, 0.93 mV;  head of ﬁbula, 0.79 mV), whereas this site of nerve
conduction velocity was  below the normal limit (42.3 m/s). This
ﬁnding indicates the presence of chronic axon degeneration in the
lower extremities. Soon after discharge from our hospital, he pre-
sented with double vision. Because of the presence of the implanted
ICD, we  could not evaluate his brain by magnetic resonance
imaging.
Subject II/1
Subject II/1, an elder brother of the proband, was  a 59-year-old
male. He had developed a cerebral infarction at 57 years of age.
During this admission, he was  pointed out to have LV hypertro-
phy and was  followed up for hypertrophic cardiomyopathy. His
ECG and echocardiographic ﬁndings were similar to those of sub-
ject II/2 (Figs. 1 and 2). We  also found an absence of GLA activity
in his plasma (Table 1), thus leading to the diagnosis of Fabry
disease. Coronary angiography showed normal coronary artery,
and the results from endomyocardial biopsy showed the same
ﬁndings as were observed in subject II/2 (Fig. 3). He had also experi-
enced episodes of acroparesthesias, but lacked any manifestations
in other organs.
Subject II/3
Subject II/3 was a ﬁrst cousin of subjects II/1 and II/2 (Fig. 4).
He also had experienced an episode of acroparesthesias, and had a
history of transient ischemic attack (TIA) at the age of 52 years. His
laboratory data showed proteinuria with a slightly reduced eGFR
and an absence of plasma GLA activity (Table 1). His ECG showed
high voltage of the QRS complex, and echocardiography showed
mild LV hypertrophy (Figs. 1 and 2).
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dig. 1. Twelve-lead electrocardiogram (ECG) of hemizygous adult males. (A) II/1 dis
s  similar to that of II/1. (C) II/3 displayed left axis deviation, high voltage of the QRS
ubjects III/1 and IV/1–3
Subject III/1 was an asymptomatic daughter of subject II/2. Sub-
ects IV/1 and IV/2 were daughters, and IV/3 was a son, of subject
II/1 (Fig. 4). None of them showed any cardiac, neurological, or
enal symptoms. The activity of plasma GLA was decreased in
ubjects III/1, IV/1, IV/2, and completely lacking in subject IV/3
Table 1).
olecular genetic ﬁndings of the family
In the male subjects in this study including II/1, 2, 3, and IV/3, a
ovel missense mutation was identiﬁed at codon 220 in exon 5, thus
esulting in an arginine (CGA) to proline (CCA) substitution (Fig. 5).
hese ﬁndings conﬁrmed that they were hemizygous males with
abry disease. On the other hand, subjects III, IV/1, and IV/2 were
iagnosed as heterozygous carriers of Fabry disease, as shown in
ig. 5.
iscussion
In this report, we presented a Japanese family with Fabry disease
howing a novel missense mutation. We  considered these individ-
als to have the classic type of Fabry disease based on their clinical
henotype and lack of plasma GLA activity. All of the hemizygous
ales predominantly presented with cardiac and cerebrovascular
anifestations in their 50 s. To the best of our knowledge, this is
he ﬁrst study showing the presence of the R220P mutation in exon
 and its relationship with the clinical features of Fabry disease. To
ate, more than 400 disease-related mutations of GLA have beend high voltages and wide QRS wave complex with negative T waves. (B) ECG of II/2
 complex and ST elevation of V1–V4.
reported [7], and a recent report from Japan also identiﬁed three
novel mutations of GLA [13].
Of the seven GLA exons, exons 5 and 6 are known to be com-
mon  areas in which the disease-related mutations are present [7].
Therefore, the R220P mutation occurred in a relatively frequently
affected area of GLA. Clinically, all three hemizygous male showed
not only cardiac manifestations but also neurological manifesta-
tions. Therefore, this family seems to be characterized into the
classic type of Fabry disease. According to previous data, a R220X
nonsense mutation was documented as the cause of classic type of
Fabry disease in Japanese [14] and in Australian families [15]. These
reports described members of these families with cardiac, neuro-
logical, and renal manifestations. In our case, we  took the histories
of other members of the family who died of chronic renal failure
(CRF). Therefore, no major differences were observed in the pheno-
types between our family with the R220P mutation and those with
the R220X mutation.
In this study, three adult hemizygous males showed LV hyper-
trophy with typical histological ﬁndings. In addition, subject II/2
developed complete atrioventricular block resulting in permanent
pacemaker implantation. This type of arrhythmia is a relatively
rare, but potentially fatal complication in Fabry patients [16,17].
The LV myocardium in Fabry patients is known to include a
progressive accumulation of glycosphingolipids, predominantly
globotriasylceramide (GL3) [16,18]. Ikari et al. revealed a con-
siderable deposition of glycosphingolipids to exist in the bundle
of His and the bundle branches in Fabry patients showing
complete atrioventricular block [16]. It is therefore strongly rec-
ommended that Fabry patients should be evaluated by ambulatory
ECG, especially those with LV hypertrophy and episodes of syn-
cope.
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able 1
linical characteristics of family members.
Subjects Age/sex (y) P-GLA activity
(nmol/h/ml)
Genetic
diagnosis
Creatinine
(mg/dl)
eGFR
(ml/min/1.73 
II/1 59M 0 Hemizygote 0.56 119.0 
II/2  (proband) 57M 0 Hemizygote 0.80 77.6 
II/3  56M 0 Hemizygote 0.79 79.0 
III  37F 1.3 Heterozygous 0.46 118.0 
IV/1  17F 3.4 Heterozygous 0.53 – 
IV/2  11F 8.2 Heterozygous 0.55 – 
IV/3  8M 0 Hemizygote 0.32 – 
GFR was calculated using a validated equation based on the Modiﬁcation of Diet in Rena
able  2
rimer sequences for ampliﬁcation of the GLA gene.
Fragment Nucleotide position 
Genomic DNA ampliﬁcation
Exons 5–7 10,078–10,094 
11,301–11,285 
Sequencing primer
Exon 5 reverse 10,349–10,365 y (LVH) with preserved EF in subject II/1 and (B) subject II/2. (C) Subject II/3 shows
m2)
Qualitative
proteinuria
BNP
(pg/ml)
Cardiac
complications
Neurological
complications
(–) 713.1 LVH Ischemic stroke
(57 y)
Acroparesthesias
(2+) 152.4 LVH
Complete AVB
(57 y)
Double vision
(57 y)
Axon
degeneration
in peroneal
nerve
Acroparensthesias
(1+) 30.1 LVH TIA (52 y)
Acroparesthesias
(–) 20.5 Normal
(–) 5.8 Normal
(–) 9.0 Normal
(–) – Normal Acroparesthesias
l Disease study in Japan
Sequence Size (bp)
Forward:
5′-CTCACAAGGATGTTAGT-3′
1224
Reverse:
5′-CAGGAAGTAGTAGTTGG-3′
5′-TATTTACCTTGAATGTC-3′
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Fig. 3. The histological ﬁnding of subject II/1. Light microscopic ﬁndings show (A) 
nd  (B) interstitial myocardial ﬁbrosis (Azan–Mallory stain, 200×). (C) Electron mi
tructure (original magniﬁcation: 4800×, the scale bar represents 1 m).
The current therapeutic approaches for Fabry disease aim to
ncrease the GLA activity, and thereby decrease the GL3 levels. To
ate, the methods to achieve this have included enzyme replace-
ent therapy (ERT) [19,20], molecular chaperone therapy [21], and
ene therapy [22]. Because only ERT is clinically available at the
resent time, we are planning to start this therapy for subjects II/1,
I/2, and II/3. Subject IV/3 has been regularly checked by a pediatri-
ian to determine an adequate start time for ERT. We  will start ERT
hen he presents with proteinuria or an elevation of the urinary
ig. 4. The pedigree of the family. The shaded square indicates hemizygous male, and the clasmic vacuolization of the myocardial cells (hematoxylin and eosin stain, 200×),
py shows the central vacuolar degeneration of myocytes with concentric lamellar
GL3 level, because the use of ERT before signiﬁcant organ damage is
important for achieving optimal therapeutic outcomes for patients
with Fabry disease [23].
Subjects II/1 and II/3 both had past histories of ischemic stroke in
their early 50 s. On the other hand, subject II/2 presented with dou-
ble vision and abnormality of nerve conduction test in the lower
extremities. Therefore, all these adult hemizygous males showed
neurological manifestations in later adulthood. Ischemic stroke
is one of the potentially life-threatening complications of Fabry
ircles with a dot indicate heterozygous female carrier. The arrow indicates proband.
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[
[Fig. 5. (A) Chromatography of normal control and (B) gen
isease, along with end-stage renal disease (ESRD) and cardiac
isease. The pathogenesis of ischemic stroke in Fabry disease is
ikely to involve speciﬁc mechanisms related directly or indirectly
o glycolipid deposition in vessel walls. According to the Fabry Out-
ome Survey (FOS) database, in patients with TIA, the proportion
f LV hypertrophy was higher (67%) than that in patients without
IA (29%) [7]. It is therefore suggested that the co-existence of LV
ypertrophy and TIA is relatively common in patients with
abry disease who survive to later adulthood without renal
ailure.
As mentioned above, classic Fabry disease is usually associ-
ted with not only interfamilial, but also intrafamilial variation in
henotype. However, it is currently difﬁcult to estimate the phe-
otype of manifestations based on only the information provided
y a genotype analysis, because there are few data supporting the
enotype–phenotype correlation in Fabry disease, and also because
uch a large number of mutations have so far been identiﬁed. In
 previous report, MacDermot et al. investigated the natural his-
ory of hemizygous males of Fabry disease in a large cohort study,
nd revealed the age-speciﬁc frequency of disease manifestation
24]. They concluded that “age stratiﬁcation” for this disease man-
festation may  contribute to phenotype classiﬁcation and might
e helpful for clinical management of these patients. According
o their data, about 30% of classic Fabry disease patients devel-
ped ESRD, and the mean age of onset of renal dialysis was  36.7
ears. It is known that about one-third of all Fabry disease patients
ill develop severe renal disease, thus contributing to a high rate
f death in early adulthood. On the other hand, in cases with no
ymptoms of advanced renal failure, cardiac or neurological mani-
estations become obvious in later adulthood. Of note, in the family
escribed in the present report, several other members were found
o have died of CRF. Therefore, the ﬁndings of this report suggested
hat age stratiﬁcation was partly useful for the phenotype classiﬁ-
ation of classic Fabry disease.
onclusions
The present study showed a family with classic Fabry disease
ho had a novel missense mutation, R220P. In this family, the
emizygous adult males showed cardiac and neurological mani-
estations, suggesting that the development of these complications
hould be carefully checked in families known to have a his-
ory of Fabry disease, even when they have no history of renal
ailure.
[DNA from subject III/1 and (C) subject II/2 for GLA exon5.
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